Biohaven Pharma (BHVN) Misses Q2 EPS by 172c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley upgrades CDW on stronger AI-driven server demand